Company Filing History:
1 out of 832,812 Years Active: 2009
Title: Mike Drebot: Innovator in Monoclonal Antibody Development
Introduction
Mike Drebot is a notable inventor based in Winnipeg, Canada. He has made significant contributions to the field of immunology, particularly in the development of monoclonal antibodies targeting the SARS-coronavirus. His work is crucial in the ongoing fight against viral infections and the advancement of diagnostic tools.
Latest Patents
Mike Drebot currently holds 1 patents. However, his research on Anti-SARS Monoclonal Antibodies has been pivotal. The development and immunochemical characterization of monoclonal antibody reagents that recognize the SARS-coronavirus are urgently needed. His work includes the selection of seventeen monoclonal antibodies through initial screening by ELISA, which utilized highly purified virus as the coating antigen.
Career Highlights
Drebot's career is marked by his innovative research in the field of virology. He has successfully identified five monoclonal antibodies that exhibited Western immunoblot reactivity with the denatured spike protein of the SARS virus. Notably, two of these antibodies demonstrated the ability to neutralize SARS-HCoV in vitro, showcasing their potential for therapeutic applications.
Collaborations
Mike Drebot has collaborated with notable colleagues such as Anton Andonov and Jody Berry. Their combined expertise has contributed to the advancement of research in monoclonal antibodies and their applications in diagnostics and vaccine studies.
Conclusion
Mike Drebot's work in the development of monoclonal antibodies against the SARS-coronavirus represents a significant advancement in immunological research. His contributions are vital for the development of diagnostic tests and therapeutic strategies against viral infections.